# Lab-on-a-Chip and Microfluidics Technologies for Nano Drug Delivery

## TL;DR

Lab-on-a-Chip and microfluidics are transforming nano drug delivery by enabling precise, high-throughput, and integrated development of nanoparticles.

## Contribution

The paper reviews recent advances in microfluidic technologies for nano drug delivery, emphasizing their role in improving nanoparticle formulation and biological evaluation.

## Key findings

- Microfluidic systems enhance the monodispersity and reproducibility of various nanocarriers.
- LoC platforms enable real-time characterization and adaptive formulation of nanoparticles.
- Emerging trends like AI-driven optimization and 3D-printed architectures are shaping future nano-pharmaceutics.

## Abstract

Lab-on-a-Chip (LoC) and microfluidic technologies are rapidly reshaping the development pipeline for nano drug delivery systems (DDSs) by enabling precise control of physicochemical properties, high-throughput screening, and integrated biological evaluation within miniaturized platforms. This review synthesizes recent advances in microfluidic principles, fabrication strategies, and sensing modalities that facilitate continuous flow synthesis, real-time characterization, and adaptive formulation of nanoparticles. We highlight how LoC-enabled systems improve monodispersity, reproducibility, and tunability of liposomes, polymeric nanoparticles, and metallic nanocarriers, while providing powerful tools for assessing pharmacokinetics, drug release, and systemic responses using organ-on-chip (OoC) models. Emerging trends, including AI-driven autonomous optimization, stimuli-responsive materials, 3D-printed hybrid architectures, and self-powered portable devices, are discussed in the context of future integrated nano-pharmaceutics platforms. Despite existing challenges related to biocompatibility, standardization, data integration, and translation to industrial and clinical applications, the synergistic evolution of LoC engineering and nanomedicine holds transformative potential for personalized and next-generation therapeutic strategies.